Sinovac Biotech Ltd. specializes in the research, development, and commercialization of human vaccines for infectious diseases such as Hepatitis A and Hepatitis B, influenza, “SARS”, avian influenza, etc. Sinovac is one of the leading emerging biotechnology companies in China.

Working closely with Chinese public health officials, Sinovac focuses on manufacturing and marketing human-use vaccines and related products, and currently markets its Hepatitis A vaccine and Hepatitis A&B vaccine. Sinovac is the first company in the world to have been granted permission to conduct clinical trials for a vaccine to prevent SARS, and is the only one having completed phase I clinical trial on SARS vaccine.

Sinovac aims to promote and develop Chinese biotech industry. By taking the advanced technologies and management mechanism, Sinovac focuses on manufacturing and marketing human-use vaccines and relative products, as well as technical consulting and services in order to make contribution to human health by improving people’s preventive capabilities against serious diseases.